Eli Lilly | LLY - Trade Creditors


Eli Lilly reported $5.03B in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Abbott USD 4.24B 117M Dec/2025
ALKERMES USD 102.36M 5.59M Mar/2026
Amgen USD 19.52B 1.37B Mar/2026
AstraZeneca USD 22.51B 2.78B Mar/2026
Baxter International USD 1.09B 87M Mar/2026
Biogen USD 358.5M 73.5M Mar/2026
Bristol-Myers Squibb USD 4.23B 659M Mar/2026
Coherus Biosciences USD 9.91M 14.98M Dec/2025
Drreddys Laboratories INR 454.04M 854K Dec/2025
Eli Lilly USD 5.03B 350M Mar/2026
Gilead Sciences USD 645M 70M Mar/2026
GlaxoSmithKline GBP 14.34B 1.05B Mar/2026
Glaxosmithkline GBP 20.72B 346.14M Dec/2025
J&J USD 10.46B 1.53B Mar/2026
Medtronic USD 2.57B 12M Dec/2025
Merck USD 3.86B 541M Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Novartis USD 4.32B 134M Mar/2026
Novartis USD 4.46B 99M Dec/2025
Novo Nordisk DKK 14.8B 4.96B Mar/2026
Perrigo USD 434.8M 39.7M Mar/2026
Pfizer USD 4.51B 734M Mar/2026
Phibro Animal Health USD 129.64M 3.65M Mar/2026
Prestige Brands USD 22.79M 20.15M Mar/2026
Regeneron Pharmaceuticals USD 1.03B 4.81B Mar/2026
Roche Holding CHF 5.78B 1.27B Dec/2025
Sanofi EUR 22.71B 219M Mar/2026
Sanofi EUR 22.93B 2.89B Dec/2025
United Therapeutics USD 498.3M 491.2M Mar/2026
Zoetis USD 507M 20M Mar/2026